Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2015 09:00 ET | Source: Tufts Center for the Study of Drug Development

Innovation in Drug Development Process Remains a Key Challenge, Tufts Center for the Study of Drug Development Says

BOSTON, MA--(Marketwired - Oct 20, 2015) - Although pharmaceutical companies have long aspired to improve drug development efficiency, the drug development process remains highly inefficient and...
September 16, 2015 09:00 ET | Source: Tufts Center for the Study of Drug Development

Adverse Drug Event Reporting in U.S. Beset by Incompleteness and Inaccuracy, According to the Tufts Center for the Study of Drug Development

BOSTON, MA--(Marketwired - Sep 16, 2015) - Voluntary adverse drug event (ADE) reporting in the United States is incomplete, inaccurate, and inefficient, which could deny or limit patient access to...
August 19, 2015 09:00 ET | Source: Tufts Center for the Study of Drug Development

Personalized Medicine Development Tied to Showing Value of Companion Diagnostics, Tufts Center for the Study of Drug Development Says

BOSTON, MA--(Marketwired - Aug 19, 2015) - With interest in personalized medicines growing, drug and diagnostics companies are investing in the development of companion diagnostics that can show...
July 09, 2015 09:00 ET | Source: Tufts Center for the Study of Drug Development

Vaccine Products in Development Have Tripled Over Last Decade, Tufts Center for the Study of Drug Development Study Says

BOSTON, MA--(Marketwired - Jul 9, 2015) - Vaccine products in the R&D pipeline have more than tripled since 2005 and annual worldwide sales are on track to reach $40 billion by 2020, according...
May 14, 2015 09:00 ET | Source: Tufts Center for the Study of Drug Development

Personalized Medicine Is Gaining Traction, but Faces Multiple Challenges, Tufts Center for the Study of Drug Development Study Concludes

BOSTON, MA--(Marketwired - May 14, 2015) - While development of personalized medicines has grown since the human genome was first sequenced in 2001, biopharmaceutical sponsors face a number of...
April 21, 2015 09:00 ET | Source: Tufts Center for the Study of Drug Development

Biopharma Summit Set for May 12 on Re-Engineering Clinical Trials to Improve Drug Development and Performance

BOSTON, MA--(Marketwired - Apr 21, 2015) - Responding to the mounting challenges of highly inefficient and costly clinical trials, which have stymied R&D productivity, the Tufts Center for the...
April 14, 2015 09:00 ET | Source: Tufts Center for the Study of Drug Development

Early BTD Projects Offer Lessons for Drug Companies, Tufts Center for the Study of Drug Development Says

BOSTON, MA--(Marketwired - Apr 14, 2015) - Flexibility and a willingness to learn from each other are key factors that enable drug companies and regulators to engage successfully in...
March 05, 2015 09:00 ET | Source: Tufts Center for the Study of Drug Development

U.S. Biosimilar Approvals Poised to Grow, but Market Uptake Faces Several Challenges, According to the Tufts Center for the Study of Drug Development

BOSTON, MA--(Marketwired - Mar 5, 2015) - Biosimilar approvals in the United States are expected to increase during the next five years, but safety concerns among physicians and the need for...
January 29, 2015 09:00 ET | Source: Tufts Center for the Study of Drug Development

Sponsors and CROs Implementing New Ways to Better Leverage Investigative Site Relationships, According to the Tufts Center for the Study of Drug Development

BOSTON, MA--(Marketwired - Jan 29, 2015) - Improved investigative site relationship use and effectiveness are top objectives in 2015 for pharmaceutical companies and contract research...
January 15, 2015 09:00 ET | Source: Tufts Center for the Study of Drug Development

High Turnover and Protocol Noncompliance Continue to Plague the Global Investigative Site Landscape, According to the Tufts Center for the Study of Drug Development

BOSTON, MA--(Marketwired - Jan 15, 2015) - Global clinical trial performance and efficiency are hampered by high turnover and noncompliance among principal investigators and wide variation in...